BR112015019039A2 - antagonistas de integrina fluorados - Google Patents

antagonistas de integrina fluorados

Info

Publication number
BR112015019039A2
BR112015019039A2 BR112015019039A BR112015019039A BR112015019039A2 BR 112015019039 A2 BR112015019039 A2 BR 112015019039A2 BR 112015019039 A BR112015019039 A BR 112015019039A BR 112015019039 A BR112015019039 A BR 112015019039A BR 112015019039 A2 BR112015019039 A2 BR 112015019039A2
Authority
BR
Brazil
Prior art keywords
fluorinated
compounds
integrin antagonists
macular edema
methods
Prior art date
Application number
BR112015019039A
Other languages
English (en)
Other versions
BR112015019039B1 (pt
BR112015019039A8 (pt
Inventor
C Askew Ben
E Duggan Mark
W Heidebrecht Richard
D Edwards Scott
Furuya Takeru
Original Assignee
Scifluor Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scifluor Life Sciences Inc filed Critical Scifluor Life Sciences Inc
Priority to BR122019026750-2A priority Critical patent/BR122019026750B1/pt
Publication of BR112015019039A2 publication Critical patent/BR112015019039A2/pt
Publication of BR112015019039A8 publication Critical patent/BR112015019039A8/pt
Publication of BR112015019039B1 publication Critical patent/BR112015019039B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

resumo “antagonistas de integrina fluorados” a presente invenção refere-se a compostos fluorados de fórmula i e a méto-dos para sintetizar esses compostos. a presente invenção também se refere a com-posições farmacêuticas contendo os compostos fluorados da invenção, e a métodos para tratar degeneração macular, retinopatia diabética (rd), edema macular, edema macular diabético (emd), e edema macular após oclusão venosa retiniana (ovr), administrando-se esses compostos e composições farmacêuticas a indivíduos em necessidade dos mesmos.
BR112015019039-1A 2013-02-07 2014-02-07 Compostos antagonistas de integrina fluorados e composição farmacêutica compreendendo os ditos compostos BR112015019039B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019026750-2A BR122019026750B1 (pt) 2013-02-07 2014-02-07 Compostos antagonistas de integrina fluorados

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361762087P 2013-02-07 2013-02-07
US61/762,087 2013-02-07
US201361900706P 2013-11-06 2013-11-06
US61/900,706 2013-11-06
PCT/US2014/015372 WO2014124302A1 (en) 2013-02-07 2014-02-07 Fluorinated integrin antagonists

Publications (3)

Publication Number Publication Date
BR112015019039A2 true BR112015019039A2 (pt) 2017-07-18
BR112015019039A8 BR112015019039A8 (pt) 2019-11-12
BR112015019039B1 BR112015019039B1 (pt) 2022-03-03

Family

ID=51300167

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019026750-2A BR122019026750B1 (pt) 2013-02-07 2014-02-07 Compostos antagonistas de integrina fluorados
BR112015019039-1A BR112015019039B1 (pt) 2013-02-07 2014-02-07 Compostos antagonistas de integrina fluorados e composição farmacêutica compreendendo os ditos compostos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019026750-2A BR122019026750B1 (pt) 2013-02-07 2014-02-07 Compostos antagonistas de integrina fluorados

Country Status (24)

Country Link
US (6) US9518053B2 (pt)
EP (3) EP2953948B1 (pt)
JP (2) JP6494528B2 (pt)
KR (1) KR102216091B1 (pt)
CN (2) CN105246889B (pt)
AU (1) AU2014214737B2 (pt)
BR (2) BR122019026750B1 (pt)
CA (1) CA2899321C (pt)
CY (1) CY1120213T1 (pt)
DK (1) DK2953948T3 (pt)
ES (2) ES2763556T3 (pt)
HK (2) HK1217696A1 (pt)
HR (1) HRP20171873T1 (pt)
HU (1) HUE035357T2 (pt)
IL (2) IL240181A (pt)
LT (1) LT2953948T (pt)
ME (1) ME02938B (pt)
PL (1) PL2953948T3 (pt)
PT (1) PT2953948T (pt)
RS (1) RS56711B1 (pt)
RU (1) RU2698195C2 (pt)
SI (1) SI2953948T1 (pt)
WO (1) WO2014124302A1 (pt)
ZA (1) ZA201505575B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
JP6494528B2 (ja) 2013-02-07 2019-04-03 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ化インテグリンアンタゴニスト
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
WO2015175954A1 (en) * 2014-05-16 2015-11-19 Scifluor Life Sciences, Inc. Alpha v integrin antagonist compositions
AU2016219906B2 (en) * 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
RU2017141561A (ru) 2015-04-30 2019-05-31 Сайфлуор Лайф Сайенсиз, Инк. Производные тетрагидронафтиридинилпропионовой кислоты и их применение
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
WO2018009501A1 (en) * 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
CA3042684A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as .alpha.v integrin inhibitors
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
WO2021231581A1 (en) 2020-05-12 2021-11-18 Scifluor Life Sciences, Inc. METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS
WO2023230042A1 (en) * 2022-05-23 2023-11-30 Ocuterra Therapeutics, Inc. Treating diabetic retinopathy using an integrin inhibitor
WO2024006248A1 (en) * 2022-06-27 2024-01-04 Ocuterra Therapeutics, Inc. Stable ophthalmic formulations of a fluorinated integrin antagonist

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
DK0581904T3 (da) 1991-04-01 1997-12-29 Univ Duke Fremgangsmåde til inhibering af fibrose
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
AU741769B2 (en) * 1997-12-17 2001-12-06 Merck Sharp & Dohme Corp. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6677360B2 (en) * 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
EE200100317A (et) * 1998-12-16 2002-08-15 Bayer Aktiengesellschaft Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
WO2000072801A2 (en) * 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
CN1366461A (zh) 2000-02-22 2002-08-28 三得利株式会社 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
ES2280383T3 (es) 2000-07-26 2007-09-16 MERCK & CO., INC. Antagonistas de receptores de integrina alfa v.
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20050004199A1 (en) * 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
WO2003040143A1 (en) 2001-11-06 2003-05-15 Merck & Co., Inc. Amine salts of an integrin receptor antagonist
US20040053968A1 (en) * 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
JP2006518333A (ja) * 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
EP1667668B1 (en) 2003-10-01 2008-07-02 MERCK PATENT GmbH Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
CA2835214C (en) 2011-05-09 2023-08-01 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
JP6494528B2 (ja) * 2013-02-07 2019-04-03 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ化インテグリンアンタゴニスト
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
AU2016219906B2 (en) 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
RU2017141561A (ru) 2015-04-30 2019-05-31 Сайфлуор Лайф Сайенсиз, Инк. Производные тетрагидронафтиридинилпропионовой кислоты и их применение
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds

Also Published As

Publication number Publication date
JP6494528B2 (ja) 2019-04-03
PL2953948T3 (pl) 2018-03-30
CA2899321A1 (en) 2014-08-14
SI2953948T1 (en) 2018-02-28
IL240181A (en) 2016-06-30
CN105246889B (zh) 2018-07-31
RU2698195C2 (ru) 2019-08-23
AU2014214737A1 (en) 2015-08-13
DK2953948T3 (en) 2017-12-18
JP2016507571A (ja) 2016-03-10
ES2763556T3 (es) 2020-05-29
US10106537B2 (en) 2018-10-23
US20170291900A1 (en) 2017-10-12
ME02938B (me) 2018-04-20
EP3266782B1 (en) 2019-10-30
WO2014124302A1 (en) 2014-08-14
CY1120213T1 (el) 2018-12-12
JP2019108377A (ja) 2019-07-04
EP3266782A1 (en) 2018-01-10
PT2953948T (pt) 2017-12-12
HRP20171873T1 (hr) 2018-02-23
RS56711B1 (sr) 2018-03-30
BR122019026750B1 (pt) 2022-03-03
ZA201505575B (en) 2022-03-30
NZ710447A (en) 2020-10-30
US9518053B2 (en) 2016-12-13
US9717729B2 (en) 2017-08-01
EP3674301A1 (en) 2020-07-01
US20190263810A1 (en) 2019-08-29
EP2953948A4 (en) 2016-06-22
HK1248677A1 (zh) 2018-10-19
US20210163473A1 (en) 2021-06-03
IL245471A0 (en) 2016-06-30
CA2899321C (en) 2021-03-09
KR102216091B1 (ko) 2021-02-16
HUE035357T2 (en) 2018-05-02
EP2953948A1 (en) 2015-12-16
AU2014214737B2 (en) 2017-07-27
US11685737B2 (en) 2023-06-27
BR112015019039B1 (pt) 2022-03-03
CN105246889A (zh) 2016-01-13
ES2651162T3 (es) 2018-01-24
HK1217696A1 (zh) 2017-01-20
CN108690022A (zh) 2018-10-23
IL245471B (en) 2018-03-29
IL240181A0 (en) 2015-09-24
KR20150115812A (ko) 2015-10-14
US20170071939A1 (en) 2017-03-16
CN108690022B (zh) 2021-08-17
US20160075698A1 (en) 2016-03-17
US20240140942A1 (en) 2024-05-02
LT2953948T (lt) 2018-01-10
EP2953948B1 (en) 2017-09-27
RU2015137785A (ru) 2017-03-14
BR112015019039A8 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
BR112015019039A2 (pt) antagonistas de integrina fluorados
BR112017017888A2 (pt) derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
AR098989A1 (es) Composiciones farmacéuticas que comprenden azd9291
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
NZ704247A (en) Compositions and treatment for eye diseases and disorders
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201590191A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и фампридина
PE20151607A1 (es) Formulaciones de compuestos organicos
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2014, OBSERVADAS AS CONDICOES LEGAIS.